IL122650A0 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents
Azetidinone derivatives for the treatment of atherosclerosisInfo
- Publication number
- IL122650A0 IL122650A0 IL12265096A IL12265096A IL122650A0 IL 122650 A0 IL122650 A0 IL 122650A0 IL 12265096 A IL12265096 A IL 12265096A IL 12265096 A IL12265096 A IL 12265096A IL 122650 A0 IL122650 A0 IL 122650A0
- Authority
- IL
- Israel
- Prior art keywords
- atherosclerosis
- treatment
- azetidinone derivatives
- azetidinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
PCT/EP1996/002765 WO1997002242A1 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
IL122650A0 true IL122650A0 (en) | 1998-08-16 |
Family
ID=27562921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12265096A IL122650A0 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0840725A1 (hu) |
JP (1) | JP2002515852A (hu) |
KR (1) | KR19990028630A (hu) |
CN (1) | CN1197452A (hu) |
AP (1) | AP728A (hu) |
AU (1) | AU708032B2 (hu) |
BG (1) | BG102214A (hu) |
BR (1) | BR9609445A (hu) |
CA (1) | CA2225627A1 (hu) |
CZ (1) | CZ422197A3 (hu) |
EA (1) | EA199800109A1 (hu) |
HU (1) | HUP9901153A3 (hu) |
IL (1) | IL122650A0 (hu) |
MA (1) | MA23922A1 (hu) |
MX (1) | MX9800186A (hu) |
NO (1) | NO976158L (hu) |
NZ (1) | NZ311684A (hu) |
OA (1) | OA10648A (hu) |
PE (1) | PE8998A1 (hu) |
PL (1) | PL324240A1 (hu) |
SK (1) | SK178497A3 (hu) |
TR (1) | TR199701762T1 (hu) |
WO (1) | WO1997002242A1 (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0869943A1 (en) * | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
HUP9901359A3 (en) * | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
CZ304450B6 (cs) | 2000-02-16 | 2014-05-14 | Smithkline Beecham P. L. C. | Pyrimidinový derivát |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
BRPI0721697A2 (pt) | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
AU2008251467B2 (en) | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
WO2012076435A1 (en) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
WO2012080497A2 (en) | 2010-12-17 | 2012-06-21 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
TW201321382A (zh) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | 化合物 |
BR112014001665A2 (pt) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz |
BR112015017397A2 (pt) | 2013-01-25 | 2017-07-11 | Glaxosmithkline Ip Dev Ltd | compostos pirimidona bicíclica como inibidores de lp-pla2 |
KR20150111356A (ko) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화합물 |
UY35276A (es) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad de Lp-PLA2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
MX2022005615A (es) | 2019-11-09 | 2022-07-27 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
JPH11500415A (ja) * | 1994-12-22 | 1999-01-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症治療用置換アゼチジン−2−オン |
-
1996
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 BR BR9609445A patent/BR9609445A/pt unknown
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/cs unknown
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Application Discontinuation
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/xx unknown
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 IL IL12265096A patent/IL122650A0/xx unknown
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/hu unknown
- 1996-06-20 SK SK1784-97A patent/SK178497A3/sk unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/xx unknown
- 1996-06-20 PL PL96324240A patent/PL324240A1/xx unknown
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 CN CN96196661A patent/CN1197452A/zh active Pending
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 EA EA199800109A patent/EA199800109A1/ru unknown
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/ko not_active Application Discontinuation
- 1996-06-20 JP JP50477297A patent/JP2002515852A/ja active Pending
- 1996-06-28 PE PE1996000496A patent/PE8998A1/es not_active Application Discontinuation
- 1996-06-28 MA MA24298A patent/MA23922A1/fr unknown
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/no unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/es unknown
- 1998-01-28 BG BG102214A patent/BG102214A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PE8998A1 (es) | 1998-03-20 |
CA2225627A1 (en) | 1997-01-23 |
MX9800186A (es) | 1998-07-31 |
BG102214A (en) | 1998-08-31 |
KR19990028630A (ko) | 1999-04-15 |
JP2002515852A (ja) | 2002-05-28 |
HUP9901153A3 (en) | 1999-11-29 |
AU6305096A (en) | 1997-02-05 |
AU708032B2 (en) | 1999-07-29 |
NO976158L (no) | 1998-02-25 |
OA10648A (en) | 2002-09-25 |
MA23922A1 (fr) | 1996-12-31 |
HUP9901153A2 (hu) | 1999-08-30 |
SK178497A3 (en) | 1998-07-08 |
BR9609445A (pt) | 1999-04-06 |
TR199701762T1 (xx) | 1998-05-21 |
AP9701161A0 (en) | 1998-01-31 |
EP0840725A1 (en) | 1998-05-13 |
NZ311684A (en) | 2000-04-28 |
WO1997002242A1 (en) | 1997-01-23 |
EA199800109A1 (ru) | 1998-10-29 |
NO976158D0 (no) | 1997-12-30 |
CN1197452A (zh) | 1998-10-28 |
AP728A (en) | 1999-01-29 |
PL324240A1 (en) | 1998-05-11 |
CZ422197A3 (cs) | 1998-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA959100B (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
AU4389896A (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
GB2298440B (en) | Well treatment | |
PL322277A1 (en) | Derivatives of pyrazol-4-ylobenzoyl | |
IL122650A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
AU5750796A (en) | System for the treatment of insomnia | |
GB2306473A8 (en) | Glucoxide derivatives | |
AU4247593A (en) | Imidazoles for the treatment of atherosclerosis | |
PL324451A1 (en) | Derivatives of diphenylmethylenepiperidine | |
IL126696A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
ZA969221B (en) | Indolealkyl derivatives of benzodioxanmethylamine. | |
GB9519033D0 (en) | Treatment | |
GR3036572T3 (en) | 4-amino-benzoylguanidine derivatives | |
AU3473193A (en) | Treatment for atherosclerosis | |
EP0754668A3 (de) | Fluorbenzylether-Derivate | |
GB9516349D0 (en) | Aza-anthracyclinone derivatives | |
ZA965276B (en) | Carboxamide derivatives | |
GR3036344T3 (en) | 4-mercapto-benzoylguanidine derivatives | |
AU4941796A (en) | Use of moxonidine for the treatment of atherosclerosis | |
EP0804205A4 (en) | 4-AZA-19-NORANDROSTANDERIVATE | |
HK1025510A1 (en) | Use of a 7alpha-methyl-17alpha-ethynyl-estrane derivative for the treatment of atherosclerosis | |
GB2308593A (en) | Imidazopyridedine derivatives | |
ZA968320B (en) | Treatment of atherosclerosis | |
GB9509286D0 (en) | Masonry treatment | |
GB9505805D0 (en) | Taxane derivatives |